HLA-C and cancer: Tumor somatic mutations, when present in protein-coding genes, lead to the production of abnormal proteins (neoantigens) that are presented by the major histocompatibility complex (MHC) class I. These novel peptides bind to the T cell receptor (TCR) and induce an adaptive immune response against cancer.